Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Kinnate Biopharma stock | $23.14

Learn how to easily invest in Kinnate Biopharma stock.

Kinnate Biopharma Inc
- $0.43 ( - 1.86%)

Kinnate Biopharma Inc is a biotechnology business based in the US. Kinnate Biopharma shares (KNTE) are listed on the NASDAQ and all prices are listed in US Dollars. Kinnate Biopharma employs 52 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Kinnate Biopharma

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – KNTE – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Kinnate Biopharma stock price (NASDAQ: KNTE)

Use our graph to track the performance of KNTE stocks over time.

Kinnate Biopharma shares at a glance

Information last updated 2021-10-17.
Latest market close$23.14
52-week range$17.58 - $48.75
50-day moving average $23.01
200-day moving average $23.58
Wall St. target price$47.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-2.37

Buy Kinnate Biopharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Kinnate Biopharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Kinnate Biopharma price performance over time

Historical closes compared with the close of $23.14 from 2021-10-21

1 week (2021-10-15) -0.22%
1 month (2021-09-22) -1.28%
3 months (2021-07-22) 7.68%
6 months (2021-04-22) -12.68%
1 year (2020-10-18) N/A
2 years (2019-10-18) N/A
3 years (2018-10-18) N/A
5 years (2016-10-18) N/A

Kinnate Biopharma financials

Gross profit TTM $0
Return on assets TTM -9.41%
Return on equity TTM -15.25%
Profit margin 0%
Book value $8.28
Market capitalisation $1 billion

TTM: trailing 12 months

Shorting Kinnate Biopharma shares

There are currently 2.0 million Kinnate Biopharma shares held short by investors – that's known as Kinnate Biopharma's "short interest". This figure is 11.4% up from 1.8 million last month.

There are a few different ways that this level of interest in shorting Kinnate Biopharma shares can be evaluated.

Kinnate Biopharma's "short interest ratio" (SIR)

Kinnate Biopharma's "short interest ratio" (SIR) is the quantity of Kinnate Biopharma shares currently shorted divided by the average quantity of Kinnate Biopharma shares traded daily (recently around 199994.42231076). Kinnate Biopharma's SIR currently stands at 10.04. In other words for every 100,000 Kinnate Biopharma shares traded daily on the market, roughly 10040 shares are currently held short.

To gain some more context, you can compare Kinnate Biopharma's short interest ratio against those of similar companies.

However Kinnate Biopharma's short interest can also be evaluated against the total number of Kinnate Biopharma shares, or, against the total number of tradable Kinnate Biopharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Kinnate Biopharma's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Kinnate Biopharma shares in existence, roughly 50 shares are currently held short) or 0.1207% of the tradable shares (for every 100,000 tradable Kinnate Biopharma shares, roughly 121 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Kinnate Biopharma.

Find out more about how you can short Kinnate Biopharma stock.

Kinnate Biopharma share dividends

We're not expecting Kinnate Biopharma to pay a dividend over the next 12 months.

You may also wish to consider:

Kinnate Biopharma overview

Kinnate Biopharma Inc. , a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers. It develops KIN-2787, which is a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors (FGFR)2 and FGFR3 genes; and small molecule research programs, including a Cyclin-Dependent Kinase 12 inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Diego, California. .

Frequently asked questions

What percentage of Kinnate Biopharma is owned by insiders or institutions?
Currently 15.022% of Kinnate Biopharma shares are held by insiders and 87.882% by institutions.
How many people work for Kinnate Biopharma?
Latest data suggests 52 work at Kinnate Biopharma.
When does the fiscal year end for Kinnate Biopharma?
Kinnate Biopharma's fiscal year ends in December.
Where is Kinnate Biopharma based?
Kinnate Biopharma's address is: 11975 El Camino Real, San Diego, CA, United States, 92130
What is Kinnate Biopharma's ISIN number?
Kinnate Biopharma's international securities identification number is: US49705R1059

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site